复星医药控股子公司注射用奈达铂获药品注册申请受理

Core Viewpoint - Fosun Pharma's subsidiary, Gismed (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of injectable Nedaplatin, which is a self-developed chemical drug intended for various cancers [1] Group 1 - The drug Nedaplatin is designed for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular tumors, ovarian cancer, and cervical cancer [1]